OMONTYS PRESERVATIVE FREE
LOE ApproachingNDAINTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Mar 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMONTYS PRESERVATIVE FREE is a small-molecule solution administered intravenously or subcutaneously, approved by the FDA in March 2012. The specific indication and mechanism of action are not publicly detailed in available data. This preservative-free formulation represents a refinement of the parent product targeting patient safety and tolerability.
LOE Approaching1mo to LOE
Product faces loss of exclusivity in mid-2026 with minimal commercial data available, suggesting either a niche market or mature/declining commercial footprint with likely team right-sizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on OMONTYS PRESERVATIVE FREE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.